177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Leptomeningeal MetastasisSolid Tumor, Adult
Interventions
BIOLOGICAL

radiolabeled DPTA-omburtamab

Biological, radiolabeled DPTA-omburtamab

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

21287

Johns Hopkins, Baltimore

27710

Duke Cancer Center, Durham

77030

M.D. Anderson Cancer Center, Houston

90048

Cedars-Sinai Medical Center, Los Angeles

98109

The University of Washington, Seattle

Unknown

The Christie Hospital NHS Foundation Trust, Manchester

The Royal Marsden Hospital, Sutton

Sponsors
All Listed Sponsors
lead

Y-mAbs Therapeutics

INDUSTRY